Literature DB >> 23714112

The level of fatty acid-binding protein 4, a novel adipokine, is increased in rheumatoid arthritis and correlates with serum cholesterol levels.

Lucie Andrés Cerezo1, Markéta Kuklová, Hana Hulejová, Zdeňka Vernerová, Vlasta Pešáková, Ondřej Pecha, David Veigl, Martin Haluzík, Karel Pavelka, Jiří Vencovský, Ladislav Senolt.   

Abstract

OBJECTIVE: To assess the expression of the novel adipokine Fatty Acid Binding Protein-4 (FABP4) in synovial tissues, serum and the synovial fluid of patients with rheumatoid arthritis (RA) and osteoarthritis (OA) and to study the relationships among FABP4, disease activity and metabolic status.
METHODS: FABP4 levels were measured in the serum and synovial fluid of 40 patients with RA and 40 control patients with OA. The disease activity score (DAS28), C-reactive protein (CRP) levels and serum lipids were assessed in patients with RA. Immunohistochemical analysis and confocal microscopy were used to study the expression and cell-specific distribution of FABP4 in synovial tissues.
RESULTS: The age, sex and body mass index (BMI) adjusted levels of FABP4 were significantly higher in the serum (p=0.001) and synovial fluid (p=0.005) of patients with RA when compared to OA patients. FABP4 levels were higher in females than in males and correlated positively with body mass index (BMI) in patients with RA. Independent of confounders, FABP4 levels correlated with total cholesterol and LDL cholesterol in patients with RA, but not in OA patients. FABP4 levels were not affected by disease activity. Furthermore, the increased expression of FABP4 that was otherwise restricted to synovial fibroblasts, macrophages and B-cells was noted in RA patients at levels higher than that observed in OA patients.
CONCLUSIONS: The observed elevation of FABP4 levels in RA patients and the positive correlation of the adipokine to cholesterol suggest that FABP4 may represent a potential link between RA and the increased risk of atherosclerotic changes.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  FABP4; Inflammation; Lipid profile; Rheumatoid arthritis

Mesh:

Substances:

Year:  2013        PMID: 23714112     DOI: 10.1016/j.cyto.2013.05.001

Source DB:  PubMed          Journal:  Cytokine        ISSN: 1043-4666            Impact factor:   3.861


  6 in total

Review 1.  Adipokines in bone disease.

Authors:  Elena Neumann; Susann Junker; Georg Schett; Klaus Frommer; Ulf Müller-Ladner
Journal:  Nat Rev Rheumatol       Date:  2016-04-15       Impact factor: 20.543

2.  Maternal Proinflammatory Adipokines Throughout Pregnancy and Neonatal Size and Body Composition: A Prospective Study.

Authors:  Ellen C Francis; Mengying Li; Stefanie N Hinkle; Jinbo Chen; Jing Wu; Yeyi Zhu; Haiming Cao; Michael Y Tsai; Liwei Chen; Cuilin Zhang
Journal:  Curr Dev Nutr       Date:  2021-09-07

3.  Calgizzarin (S100A11): a novel inflammatory mediator associated with disease activity of rheumatoid arthritis.

Authors:  Lucie Andrés Cerezo; Barbora Šumová; Klára Prajzlerová; David Veigl; Dres Damgaard; Claus Henrik Nielsen; Karel Pavelka; Jiří Vencovský; Ladislav Šenolt
Journal:  Arthritis Res Ther       Date:  2017-04-26       Impact factor: 5.156

4.  Biological Effects of Phosphocitrate on Osteoarthritic Articular Chondrocytes.

Authors:  Yubo Sun; Atiya M Franklin; David R Mauerhan; Edward N Hanley
Journal:  Open Rheumatol J       Date:  2017-05-31

5.  Progranulin Is Associated with Disease Activity in Patients with Rheumatoid Arthritis.

Authors:  Lucie Andrés Cerezo; Markéta Kuklová; Hana Hulejová; Zdeňka Vernerová; Nikola Kaspříková; David Veigl; Karel Pavelka; Jiří Vencovský; Ladislav Šenolt
Journal:  Mediators Inflamm       Date:  2015-08-03       Impact factor: 4.711

6.  Correlation of serum fatty acid binding protein-4 and interleukin-6 with airflow limitation and quality of life in stable and acute exacerbation of COPD

Authors:  Mohammad Reza Aslani; Zeynab Ghazaei; Hassan Ghobadi
Journal:  Turk J Med Sci       Date:  2020-04-09       Impact factor: 0.973

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.